Palivizumab (Synagis) for prevention of RSV infection

Article Abstract:

The drug palivizumab has been approved by the FDA for preventing respiratory syncytial virus (RSV) infection in children. Sold under the trade name Synagis, it is a human monoclonal antibody against a protein on the virus surface. RSV infection is not dangerous in healthy children, but can be quite serious in premature infants and children with lung diseases. It is effective in preventing RSV infection in these children, but it is expensive.

---

Synagis revisited

Article Abstract:

Monthly intramuscular injections of Synagis beginning in the Fall may prevent respiratory syncytial virus infections in premature babies and babies with chronic lung disease. Synagis is a monoclonal antibody against the virus but it is very expensive.

Product information, MedImmune Inc., MEDI

---

Erythropoietin (Procrit; Epogen) revisited

Article Abstract:

Recombinant erythropoietin should only be used to treat anemia caused by kidney failure, cancer, or HIV infection. It is often used by athletes to increase their endurance and is being advertised directly to consumers as an energy booster.

Health aspects, Anemia, Drug therapy, Erythropoietin, Recombinant, Recombinant erythropoietin, Epogen (Medication), Procrit (Medication)

Similar abstracts:

• Abstracts: Skills for preventing aggression. Solution-focused brief therapy in primary care. Making the connections to aid mental health: Links between mental health nurses and general nurses are increasing
• Abstracts: Syringe exchange and risk of infection with hepatitis B and C viruses. Analysis of case-control studies of screening: impact of misspecifying the duration of detectable preclinical pathologic changes
• Abstracts: Prospective study of HTLV-I infection in an initially asymptomatic cohort. Growth failure in children with HIV infection
• Abstracts: Babies who cry persistently: responses and prevention. Making babies making waves
• Abstracts: Firing lines: automatic fire doors. Fire safety in the future. Fire extinguishers use survey

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.